Following on from information provided to NICE by the company in September 2022, the appraisal of Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1667

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 September 2023 Discontinued. Following on from information provided to NICE by the company in September 2022, the appraisal of Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
16 September 2022 Suspended. As you will be aware the Department for Health & Social Care has asked NICE to carry out an appraisal of Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]. For information, the company have announced that KEYNOTE-412 trial did not meet its primary endpoint in and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.
20 May 2022 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late November 2022 when we will write to you about how you can get involved.
16 July 2021 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-January 2023 when we will write to you about how you can get involved.
19 February 2021 Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during late-October 2021 when we will write to you about how you can get involved. These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.
16 December 2019 In progress. Referred 25 March 2019

For further information on our processes and methods, please see our CHTE processes and methods manual